Beneficial Ownership Report · SCHEDULE 13G/A
Freenome, Inc.
FRNMNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Freenome, Inc.
- Company CIK
- 0002017526
- Street
- Genesis Marina, 3300 Marina Blvd
- City
- Brisbane
- State / country code
- CA
- Postal code
- 94005
Statement details
- Amendment number
- 1
- Security class
- Common Stock, $0.0001 par value
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- RTW Investments, LP
- Citizenship / organization
- DE
- Reporting person type
- IA · PN
- Aggregate amount owned
- 742,500.00
- Percent of class
- 0.7
- Sole voting power
- 0.00
- Shared voting power
- 742,500.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 742,500.00
Reporting person 2
- Name
- Roderick Wong
- Citizenship / organization
- X1
- Reporting person type
- HC · IN
- Aggregate amount owned
- 742,500.00
- Percent of class
- 0.7
- Sole voting power
- 0.00
- Shared voting power
- 742,500.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 742,500.00
Item 1
Issuer
Freenome, Inc.
Principal executive office address
Genesis Marina, 3300 Marina Blvd, Brisbane, CA, 94005.
Item 2
Citizenship
RTW Investments is a Delaware limited partnership. Dr. Wong is a citizen of the United States.
Filing person
This statement is filed by: (i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership and the investment adviser to certain funds (the "RTW Funds"), with respect to shares of Common Stock, par value $0.0001 per share (the "Shares") of Freenome, Inc. (formerly known as Perceptive Capital Solutions Corp) (the "Company") directly held by the RTW Funds; and (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein.
Principal business or residence address
The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.
Item 3
Not applicable indication
N
Type of filing person
IA · HC
Item 4
Percent of class
RTW Investments: 0.7% Dr. Wong: 0.7%
Amount beneficially owned
The information required by Item 4(a) is set forth in Rows 5 - 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentages set forth in Row 11 of the cover pages are calculated based upon 107,446,814 Shares outstanding as of August 8, 2026 as reported in the Company's prospectus dated August 27, 2026, filed with the Securities and Exchange Commission on August 27, 2026.
Sole voting power
RTW Investments: 0 Dr. Wong: 0
Shared voting power
RTW Investments: 742,500 Shares Dr. Wong: 742,500 Shares
Sole dispositive power
RTW Investments: 0 Dr. Wong: 0
Shared dispositive power
RTW Investments: 742,500 Shares Dr. Wong: 742,500 Shares
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
See Item 2. The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on November 14, 2024).
Signature 1
- Reporting person
- RTW Investments, LP
- Signed
- /s/ Roderick Wong, M.D.
- Title
- Roderick Wong, M.D., Managing Partner
- Date
- 11/16/2026
Signature 2
- Reporting person
- Roderick Wong
- Signed
- /s/ Roderick Wong, M.D.
- Title
- Roderick Wong, M.D.
- Date
- 11/16/2026
Company context
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of SimpleScreen™ CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals. For more information, visit www.freenome.com.
Current securities
Historical securities (1)
Recent company filings
- SCHEDULE 13G/A - filed by ADAR1 Capital Management, LLC regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by PERCEPTIVE ADVISORS LLC regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by Holocene Advisors, LP regarding Freenome, Inc.Nov 16, 2026
- SCHEDULE 13G/A - filed by One Fin Capital Management LP regarding Freenome, Inc.Nov 16, 2026